PureTech Health (LSE:PRTC) Net Cash per Share : £0.28 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). PureTech Health's Net Cash per Share for the quarter that ended in Dec. 2023 was £0.28.

The historical rank and industry rank for PureTech Health's Net Cash per Share or its related term are showing as below:

LSE:PRTC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.14 Med: 7.06 Max: 18.18
Current: 7.86

During the past 12 years, the highest Price-to-Net-Cash Ratio of PureTech Health was 18.18. The lowest was 2.14. And the median was 7.06.

LSE:PRTC's Price-to-Net-Cash is ranked worse than
71.48% of 873 companies
in the Biotechnology industry
Industry Median: 4.04 vs LSE:PRTC: 7.86

PureTech Health Net Cash per Share Historical Data

The historical data trend for PureTech Health's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Net Cash per Share Chart

PureTech Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

Get a 7-Day Free Trial

-0.30

0.22

0.30

0.56

0.28

PureTech Health Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Cash per Share	Get a 7-Day Free Trial															0.30	0.36	0.56	0.49	0.28

Competitive Comparison of PureTech Health's Net Cash per Share

For the Biotechnology subindustry, PureTech Health's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where PureTech Health's Price-to-Net-Cash falls into.

PureTech Health Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

PureTech Health's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(258.443	-	186.236	-	-4.61)	/	271.854
=	0.28

PureTech Health's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(258.443	-	186.236	-	-4.61)	/	271.854
=	0.28

PureTech Health (LSE:PRTC) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

PureTech Health Net Cash per Share Related Terms

Thank you for viewing the detailed overview of PureTech Health's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health (LSE:PRTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (LSE:PRTC) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

PRTC:USA PTCHF:USA PRTCl:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.